Clinical Trial

Role of Pro-Resolving Lipid Mediators in Obesity-Associated Diseases

Study acronym: RESOLBE
Recruiting
View on ClinicalTrials.gov →
Summary
The main objective of this project is to determine the possible association between the levels of certain bioactive lipids, which the body produces from dietary fatty acids, and tumor characteristics in breast cancer patients, as well as their relationship with overweight/obesity. Specific objectives are: * To analyse anthropometric and body composition changes. * To evaluate physical activity level. * To determine dietary profile. * To determine the adherence to Mediterranean dietary pattern. * To assess the quality of life. * To determine levels of specialized pro-resolving lipid mediators The target sample size is 60 subjects. Participants will be allocated in four groups: * Group 1: Postmenopausal healthy women with overweight/obesity (n=15) * Group 2: Postmenopausal healthy women with normoweight (n=15) * Group 3: Postmenopausal women with breast cancer and overweight/obesity (n=15) * Group 4: Postmenopausal women with breast cancer and normoweight (n=15)
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-25.
Trial Details
NCT Number NCT07447440
Lead Sponsor Clinica Universidad de Navarra, Universidad de Navarra
Conditions Breast Cancer, Health, Subjective, Obesity
Enrollment 60 participants
Start Date 2025-10-15
Primary Completion 2027-11-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-11